Recent Supreme Court Decisions On Inter Partes Review — What Biosimilar Developers Need To Know

The U.S. Supreme Court recently issued two decisions related to inter partes review. This article by Limin Zheng will briefly introduce IPR, discuss the Supreme Court’s decisions, explain how these decisions may impact IPR and biosimilar companies, and suggest how biosimilar companies should respond.

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *